Sarepta Therapeutics (SRPT) : On Thursday, The money flowed into the Sarepta Therapeutics (SRPT) stock with an uptick to downtick ratio was recorded at 1.29. Transactions worth $0.83 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0.64 million. The total money flow into the stock was $0.19 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.34 million of block transactions on upticks. The total money flow in block trades was $0.34 million. In terms of price action, Sarepta Therapeutics (SRPT) traded down $0.28 during the session at $21.05. Compared to the previous days closing, the stock was down only by -1.31%. For the week, the stock is -6.94%, over previous weeks closing.
The stock has recorded a 20-day Moving Average of 6.33% and the 50-Day Moving Average is 8.73%. Shares have dropped -33.22% from its 1 Year high price. On Oct 5, 2015, the shares registered one year high at $41.97 and the one year low was seen on Apr 26, 2016. The 50-Day Moving Average price is $19.18 and the 200 Day Moving Average price is recorded at $18.73.
Sarepta Therapeutics (NASDAQ:SRPT): The stock opened at $21.40 on Thursday but the bulls could not build on the opening and the stock topped out at $21.52 for the day. The stock traded down to $20.08 during the day, due to lack of any buying support eventually closed down at $20.44 with a loss of -4.17% for the day. The stock had closed at $21.33 on the previous day. The total traded volume was 2,672,745 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Sarepta Therapeutics, Inc., Behrens M Kathleen had purchased shares worth of $1,165,500 in a transaction dated on March 14, 2016. A total of 75,000 shares were purchased at a price of $15.54 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.